Home WebinarsA New Opportunity for Challenging Drug Substances: Combining 3D Printing Technology with Loading of Mesoporous Silica

A New Opportunity for Challenging Drug Substances: Combining 3D Printing Technology with Loading of Mesoporous Silica

WEBINAR

In the rapidly evolving pharmaceutical manufacturing landscape, the integration of 3D printing technology presents a groundbreaking approach to enhance efficacy and flexibility for the development of drug delivery systems.

By seamlessly merging Aprecia's commercial-scale 3D printing platform with our cutting-edge solubility enhancement technology based on Parteck^® SLC silica carrier, we are redefining manufacturing possibilities. This can be achieved through either pre-loaded carrier materials or direct integration of the silica carrier during the 3D printing process, paving the way for a new era in pharmaceutical manufacturing.

Speakers

Thomas Kipping, Ph.D.

Merck

Head of 3D Printing & Solubility Enhancement

With more than 12 years of experience in various functions within the pharmaceutical industry, Thomas holds a Ph.D. in pharmaceutical technology and provides a deep understanding of formulation and technology development in the complex area of additive manufacturing and solubility enhancement.

Michelle Schilling, Ph.D.

Aprecia Pharmaceuticals

Product Development Manager

Dr. Schilling is currently the manager of product development at Aprecia Pharmaceuticals with 14 years of pharmaceutical experience. She has been a technical leader on multiple cross-functional product development teams with expertise in formulation and process design from early development through scale-up of IR and modified-release drug products.

Her experience includes process development with 3-D printing (binder jetting), tableting, fluid-bed manufacturing, high-shear granulation, coacervation, encapsulation, and roller compaction. Michelle is a chemist by training and holds a Ph.D. in industrial and physical pharmacy from Purdue University.